TapewireFind a company

person · Reporting owner

Eldridge George A

Disclosed activity across 1 company

Tapewire entity
89879
SEC CIK
0001413006

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Jade Biosciences, Inc.AVTE · Entity 4757SEE REMARKSJune 14, 2024June 14, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Jade Biosciences, Inc.

Report date June 14, 2024 · Filed June 14, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect20,022 Reported balance After 2024-06-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2024-06-14 · Exercise / conversion · Acquired 15,000 · Balance 20,022

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2: Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).

Common StockSEC Table I · non-derivativeDirect5,022 Reported balance After 2024-06-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2024-06-14 · Sale · Disposed 15,000 · Balance 5,022

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01Direct28,763 Reported balance After 2024-06-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-06-14 · Exercise / conversion · Disposed 15,000 · Balance 28,763

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2: Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).

F3: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 14, 2024 Filed Jun 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-016995 · form4-06142024_060606.xml · derivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,763

Underlying: Common Stock · 15,000 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
June 14, 2024 Filed Jun 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 15,000 $25.03 $375,450.00
Disclosure

SEC source: 0001415889-24-016995 · form4-06142024_060606.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,022

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
June 14, 2024 Filed Jun 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 15,000 $2.14 $32,100.00
Disclosure

SEC source: 0001415889-24-016995 · form4-06142024_060606.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,022

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2 · balance_after: Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).

Read SEC document
April 10, 2024 Filed Apr 12, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 7,500 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-010773 · form4-04122024_060401.xml · derivative · entry 4

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,763

Underlying: Common Stock · 7,500 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F4 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
April 10, 2024 Filed Apr 12, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 771 $27.56 $21,252.31
Disclosure

SEC source: 0001415889-24-010773 · form4-04122024_060401.xml · nonDerivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.35 to $27.74, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 10, 2024 Filed Apr 12, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 6,729 $26.77 $180,139.37
Disclosure

SEC source: 0001415889-24-010773 · form4-04122024_060401.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,731

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.32 to $27.315, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 10, 2024 Filed Apr 12, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 7,500 $2.14 $16,050.00
Disclosure

SEC source: 0001415889-24-010773 · form4-04122024_060401.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 12,495 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-010136 · form4-04032024_060404.xml · derivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,768

Underlying: Common Stock · 12,495 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 12,495 $31.23 $390,207.60
Disclosure

SEC source: 0001415889-24-010136 · form4-04032024_060404.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 12,495 $2.14 $26,739.30
Disclosure

SEC source: 0001415889-24-010136 · form4-04032024_060404.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,455

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
March 13, 2024 Filed Mar 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 2,016 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-008033 · form4-03142024_060304.xml · derivative · entry 6

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,263

Underlying: Common Stock · 2,016 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F4 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
March 13, 2024 Filed Mar 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 2,016 $25.02 $50,444.96
Disclosure

SEC source: 0001415889-24-008033 · form4-03142024_060304.xml · nonDerivative · entry 4

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.08, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 13, 2024 Filed Mar 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,016 $2.14 $4,314.24
Disclosure

SEC source: 0001415889-24-008033 · form4-03142024_060304.xml · nonDerivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,976

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
March 12, 2024 Filed Mar 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 2,051 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-008033 · form4-03142024_060304.xml · derivative · entry 5

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,279

Underlying: Common Stock · 2,051 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F4 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
March 12, 2024 Filed Mar 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 2,051 $25.05 $51,369.55
Disclosure

SEC source: 0001415889-24-008033 · form4-03142024_060304.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.19, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 12, 2024 Filed Mar 14, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2,051 $2.14 $4,389.14
Disclosure

SEC source: 0001415889-24-008033 · form4-03142024_060304.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,011

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
March 11, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 3,433 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · derivative · entry 11

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,330

Underlying: Common Stock · 3,433 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
March 11, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 10 $26.31 $263.05
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 7

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
March 11, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 3,423 $25.24 $86,404.39
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 6

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,970

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 11, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 3,433 $2.14 $7,346.62
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 5

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
March 08, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 114 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · derivative · entry 10

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,763

Underlying: Common Stock · 114 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
March 08, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 114 $25.00 $2,850.00
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 4

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
March 08, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 114 $2.14 $243.96
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,074

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 20,986 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · derivative · entry 9

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,877

Underlying: Common Stock · 20,986 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F5 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,400 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · derivative · entry 8

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,263

Underlying: Common Stock · 1,400 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F4 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 22,386 $25.00 $559,688.06
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.289, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 22,386 $2.14 $47,906.04
Disclosure

SEC source: 0001415889-24-007534 · form4-03112024_060307.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Read SEC document
January 22, 2024 Filed Jan 24, 2024 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Options (Right to Buy) · Derivative 66,586 $0.00 Strike: $20.00 $0.00
Disclosure

SEC source: 0001415889-24-001772 · form4-01242024_060102.xml · derivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,586

Underlying: Common Stock · 66,586 shares

Expires 2034-01-21

F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.

Read SEC document
February 07, 2023 Filed Feb 8, 2023 23:10 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 85,000 $0.00 Strike: $25.57 $0.00
Disclosure

SEC source: 0001415889-23-002173 · form4-02082023_060206.xml · derivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-02-06

F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on March 7, 2023.

Read SEC document
December 12, 2022 Filed Dec 13, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 2,906 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-012508 · form4-12132022_061201.xml · derivative · entry 8

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,863

Underlying: Common Stock · 2,906 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
December 12, 2022 Filed Dec 13, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 7,094 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-012508 · form4-12132022_061201.xml · derivative · entry 7

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,663

Underlying: Common Stock · 7,094 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F5 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
December 12, 2022 Filed Dec 13, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 10,000 $30.04 $300,428.00
Disclosure

SEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 5

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.39, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
December 12, 2022 Filed Dec 13, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 10,000 $2.14 $21,400.00
Disclosure

SEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 4

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,960

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
December 09, 2022 Filed Dec 13, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 3,969 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-012508 · form4-12132022_061201.xml · derivative · entry 6

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,757

Underlying: Common Stock · 3,969 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F5 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
December 09, 2022 Filed Dec 13, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 583 $25.23 $14,710.66
Disclosure

SEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.01 to $25.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
December 09, 2022 Filed Dec 13, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 3,386 $24.23 $82,054.63
Disclosure

SEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,543

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $25.00, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
December 09, 2022 Filed Dec 13, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 3,969 $2.14 $8,493.66
Disclosure

SEC source: 0001415889-22-012508 · form4-12132022_061201.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,929

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
December 08, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 10,124 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · derivative · entry 10

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,726

Underlying: Common Stock · 10,124 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F7 · derivative.exercise_date: A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
December 08, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,887 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · derivative · entry 9

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,769

Underlying: Common Stock · 1,887 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
December 08, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 11,031 $24.20 $266,974.47
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 7

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
December 08, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 20 $20.58 $411.60
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 6

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,991

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
December 08, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 960 $20.12 $19,313.76
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 5

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,011

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.575 to $20.54, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
December 08, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 12,011 $2.14 $25,703.54
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 4

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,971

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
December 07, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 11,637 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · derivative · entry 8

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,656

Underlying: Common Stock · 11,637 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
December 07, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 4,558 $20.40 $92,992.77
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
December 07, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 7,079 $19.37 $137,089.79
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,518

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.97, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
December 07, 2022 Filed Dec 9, 2022 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 11,637 $2.14 $24,903.18
Disclosure

SEC source: 0001415889-22-012355 · form4-12092022_061201.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
November 30, 2022 Filed Dec 3, 2022 00:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 85 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-011982 · form4-12022022_071201.xml · derivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,293

Underlying: Common Stock · 85 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F3 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 30, 2022 Filed Dec 3, 2022 00:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 85 $19.06 $1,620.13
Disclosure

SEC source: 0001415889-22-011982 · form4-12022022_071201.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 30, 2022 Filed Dec 3, 2022 00:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 85 $2.14 $181.90
Disclosure

SEC source: 0001415889-22-011982 · form4-12022022_071201.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.